Results 161 to 170 of about 8,866 (177)

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

Trends in kinase drug discovery: targets, indications and inhibitor design

Nature Reviews Drug Discovery, 2021
Misty M Attwood, Stefan Knapp
exaly  

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Nature Reviews Clinical Oncology, 2022
Lecia V Sequist, Jessica J Lin
exaly  

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell, 2020
Markus Hoffmann, Nadine Krüger, Tobias S Schiergens   +2 more
exaly  

Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors

Ca-A Cancer Journal for Clinicians, 2011
Kiran K Turaga
exaly  

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy-induced amenorrhea

Ca-A Cancer Journal for Clinicians, 2018
Clement Chung
exaly  

The adenosine pathway in immuno-oncology

Nature Reviews Clinical Oncology, 2020
Bertrand Allard, Laurence Buisseret, John Stagg   +2 more
exaly  

NTRK fusion-positive cancers and TRK inhibitor therapy

Nature Reviews Clinical Oncology, 2018
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon   +2 more
exaly  

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

Nature Reviews Clinical Oncology, 2016
Fausto Castagnetti, Michele Baccarani
exaly